Safety and efficacy of tazarotene foam for the treatment of acne vulgaris
Tazarotene foam is the first topical retinoid foam approved for the treatment of acne vulgaris. To review the safety and efficacy studies of tazarotene foam in the treatment of moderate to severe acne. Five Phase I safety studies in normal controls are reviewed and two Phase III safety and efficacy...
Saved in:
| Published in: | Clinical, cosmetic and investigational dermatology Vol. 6; no. default; pp. 123 - 125 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | English |
| Published: |
New Zealand
Dove Medical Press Limited
01-01-2013
Taylor & Francis Ltd Dove Medical Press |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Tazarotene foam is the first topical retinoid foam approved for the treatment of acne vulgaris.
To review the safety and efficacy studies of tazarotene foam in the treatment of moderate to severe acne.
Five Phase I safety studies in normal controls are reviewed and two Phase III safety and efficacy studies in patients with moderate to severe acne are reviewed.
Tazarotene foam, 0.1% was effective in the treatment of moderate to severe acne vulgaris with an acceptable tolerability profile. This treatment provides a cosmetically favorable alternative for topical retinoid therapy. |
|---|---|
| AbstractList | Background: Tazarotene foam is the first topical retinoid foam approved for the treatment of acne vulgaris. Objective: To review the safety and efficacy studies of tazarotene foam in the treatment of moderate to severe acne. Methods: Five Phase I safety studies in normal controls are reviewed and two Phase III safety and efficacy studies in patients with moderate to severe acne are reviewed. Conclusion: Tazarotene foam, 0.1% was effective in the treatment of moderate to severe acne vulgaris with an acceptable tolerability profile. This treatment provides a cosmetically favorable alternative for topical retinoid therapy. Tazarotene foam is the first topical retinoid foam approved for the treatment of acne vulgaris. To review the safety and efficacy studies of tazarotene foam in the treatment of moderate to severe acne. Five Phase I safety studies in normal controls are reviewed and two Phase III safety and efficacy studies in patients with moderate to severe acne are reviewed. Tazarotene foam, 0.1% was effective in the treatment of moderate to severe acne vulgaris with an acceptable tolerability profile. This treatment provides a cosmetically favorable alternative for topical retinoid therapy. Background: Tazarotene foam is the first topical retinoid foam approved for the treatment of acne vulgaris. Objective: To review the safety and efficacy studies of tazarotene foam in the treatment of moderate to severe acne. Methods: Five Phase I safety studies in normal controls are reviewed and two Phase III safety and efficacy studies in patients with moderate to severe acne are reviewed. Conclusion: Tazarotene foam, 0.1% was effective in the treatment of moderate to severe acne vulgaris with an acceptable tolerability profile. This treatment provides a cosmetically favorable alternative for topical retinoid therapy. Keywords: tazarotene, acne, foam, topical retinoid Erica L Epstein, Linda Stein GoldHenry Ford Hospital, Detroit, MI, USABackground: Tazarotene foam is the first topical retinoid foam approved for the treatment of acne vulgaris.Objective: To review the safety and efficacy studies of tazarotene foam in the treatment of moderate to severe acne.Methods: Five Phase I safety studies in normal controls are reviewed and two Phase III safety and efficacy studies in patients with moderate to severe acne are reviewed.Conclusion: Tazarotene foam, 0.1% was effective in the treatment of moderate to severe acne vulgaris with an acceptable tolerability profile. This treatment provides a cosmetically favorable alternative for topical retinoid therapy.Keywords: tazarotene, acne, foam, topical retinoid BACKGROUNDTazarotene foam is the first topical retinoid foam approved for the treatment of acne vulgaris. OBJECTIVETo review the safety and efficacy studies of tazarotene foam in the treatment of moderate to severe acne. METHODSFive Phase I safety studies in normal controls are reviewed and two Phase III safety and efficacy studies in patients with moderate to severe acne are reviewed. CONCLUSIONTazarotene foam, 0.1% was effective in the treatment of moderate to severe acne vulgaris with an acceptable tolerability profile. This treatment provides a cosmetically favorable alternative for topical retinoid therapy. |
| Audience | Academic |
| Author | Stein Gold, Linda Epstein, Erica L |
| Author_xml | – sequence: 1 givenname: Erica L surname: Epstein fullname: Epstein, Erica L organization: Henry Ford Hospital, Detroit, MI, USA – sequence: 2 givenname: Linda surname: Stein Gold fullname: Stein Gold, Linda |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23696711$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkk1rGzEQhpeS0qRpTr2XhUIpFLv62F2tLoXgfsQQ6CHtWcxKI1tmd5VK2oD76yvHaWKXSiCJmWfeQcP7sjgZ_YhF8ZqSOaOV-LhYLD_Pb3hF6upZcUapaGeC0Prk4H1aXMS4IXlxWQvevihOGW9kIyg9K5Y3YDFtSxhNidY6DXpbelsm-A3BJxyxtB6GfIQyrbFMASENOKYdBDqn76Z-BcHFV8VzC33Ei4f7vPj59cuPxdXs-vu35eLyeqZz8zQTsiXQCdJqxixo0nZgKt2amhJjGMGmQ2aMaEDXSKzUaJlpOya7riFctC0_L5Z7XeNho26DGyBslQen7gM-rBSE5HSPylDZVWClIbkHsaRjjErBcxMUgrCd1qe91u3UDWh0_leA_kj0ODO6tVr5O8Wbuq04zQLvHwSC_zVhTGpwUWPfw4h-ioryuhKSVLzJ6Nt_0I2fwphHpdj9kk1Dn6gV5A-40frcV-9E1SUXVUtZ3chMzf9D5W1wcDo7xLocPyp4d1CwRujTOvp-Ss6P8Rj8sAd18DEGtI_DoETtHKd2jlN7x2X6zeH8Htm__uJ_APm_z9M |
| CitedBy_id | crossref_primary_10_17116_klinderma201918021115 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2013 Dove Medical Press Limited 2013. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2013 Epstein and Gold, publisher and licensee Dove Medical Press Ltd 2013 |
| Copyright_xml | – notice: COPYRIGHT 2013 Dove Medical Press Limited – notice: 2013. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2013 Epstein and Gold, publisher and licensee Dove Medical Press Ltd 2013 |
| DBID | NPM AAYXX CITATION 3V. 7RV 7XB 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH KB0 M2O MBDVC NAPCQ PIMPY PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
| DOI | 10.2147/CCID.S34054 |
| DatabaseName | PubMed CrossRef ProQuest Central (Corporate) ProQuest Nursing and Allied Health Journals ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep Nursing & Allied Health Database (Alumni Edition) Proquest Research Library Research Library (Corporate) Nursing & Allied Health Premium Publicly Available Content (ProQuest) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | PubMed CrossRef Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest Central Basic ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Research Library (Alumni Edition) Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central Nursing & Allied Health Premium Health Research Premium Collection ProQuest One Academic UKI Edition ProQuest Central Korea ProQuest Research Library ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1178-7015 |
| EndPage | 125 |
| ExternalDocumentID | oai_doaj_org_article_d19b4af9d0ad40f0b2219730e6e77028 A374812569 10_2147_CCID_S34054 23696711 |
| Genre | Journal Article |
| GroupedDBID | --- 0YH 29B 2WC 53G 5VS 7RV 8FI 8FJ 8G5 ABUWG ADBBV ADRAZ AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BCNDV BENPR BKEYQ BPHCQ BVXVI C1A CCPQU DIK DWQXO E3Z EBD FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HYE IAO IHR IHW IPNFZ ITC KQ8 M2O M48 M~E NAPCQ NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC RIG RPM TR2 TUS UKHRP VDV AAYXX CITATION TDBHL 3V. 7XB 8FK MBDVC PQEST PQUKI PRINS Q9U 7X8 5PM |
| ID | FETCH-LOGICAL-c573t-7980ab708c22fac08bad4c8d510dd20e6be2dd76ac5e0f9cef2d8b29bb6037883 |
| IEDL.DBID | RPM |
| ISSN | 1178-7015 |
| IngestDate | Tue Oct 22 15:07:37 EDT 2024 Tue Sep 17 21:25:28 EDT 2024 Fri Aug 16 11:56:51 EDT 2024 Wed Nov 06 08:14:58 EST 2024 Tue Nov 19 21:07:41 EST 2024 Tue Nov 12 23:12:54 EST 2024 Tue Aug 20 22:12:43 EDT 2024 Thu Nov 21 21:30:53 EST 2024 Sat Sep 28 08:08:45 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | default |
| Keywords | acne topical retinoid foam tazarotene |
| Language | English |
| License | This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c573t-7980ab708c22fac08bad4c8d510dd20e6be2dd76ac5e0f9cef2d8b29bb6037883 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658431/ |
| PMID | 23696711 |
| PQID | 2222229661 |
| PQPubID | 3933178 |
| PageCount | 3 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_d19b4af9d0ad40f0b2219730e6e77028 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3658431 proquest_miscellaneous_1354790436 proquest_journals_2222229661 gale_infotracmisc_A374812569 gale_infotracacademiconefile_A374812569 gale_healthsolutions_A374812569 crossref_primary_10_2147_CCID_S34054 pubmed_primary_23696711 |
| PublicationCentury | 2000 |
| PublicationDate | 2013-01-01 |
| PublicationDateYYYYMMDD | 2013-01-01 |
| PublicationDate_xml | – month: 01 year: 2013 text: 2013-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | New Zealand |
| PublicationPlace_xml | – name: New Zealand – name: Auckland |
| PublicationTitle | Clinical, cosmetic and investigational dermatology |
| PublicationTitleAlternate | Clin Cosmet Investig Dermatol |
| PublicationYear | 2013 |
| Publisher | Dove Medical Press Limited Taylor & Francis Ltd Dove Medical Press |
| Publisher_xml | – name: Dove Medical Press Limited – name: Taylor & Francis Ltd – name: Dove Medical Press |
| References | 23652892 - J Drugs Dermatol. 2013 Apr;12(4):438-46 16989194 - J Drugs Dermatol. 2006 Sep;5(8):785-94 23259209 - Cutis. 2012 Oct;90(4):206-11 23270200 - Cutis. 2012 Nov;90(5):266-71 23456673 - Clin Drug Investig. 2013 Apr;33(4):283-9 12553848 - Am J Clin Dermatol. 2003;4(2):75-80 |
| References_xml | |
| SSID | ssj0000395738 |
| Score | 2.0047796 |
| Snippet | Tazarotene foam is the first topical retinoid foam approved for the treatment of acne vulgaris.
To review the safety and efficacy studies of tazarotene foam in... Background: Tazarotene foam is the first topical retinoid foam approved for the treatment of acne vulgaris. Objective: To review the safety and efficacy... BACKGROUNDTazarotene foam is the first topical retinoid foam approved for the treatment of acne vulgaris. OBJECTIVETo review the safety and efficacy studies of... Erica L Epstein, Linda Stein GoldHenry Ford Hospital, Detroit, MI, USABackground: Tazarotene foam is the first topical retinoid foam approved for the treatment... |
| SourceID | doaj pubmedcentral proquest gale crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 123 |
| SubjectTerms | Acne Drug therapy Medical research Medicine, Experimental Retinoids Review |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB5BD4gL4k2ggJEqcQp1nKwdH8u2VXuAy4LEzfJT9EAWdXeRyq9nxk6jjThwIYcc4kkUf-PxjF_fABw5mVIXk6gTtqe6U76rrW1FbRdRtF76RgWah7xYqc_f-tMzosmZUn3RnrBCD1yAOw6Ndp1NOnAbOp64E2hj2CyjjEqhc8y9L5d7g6ncB9PyU05j3TQ4TFLo9MrhPErLc7xcXp5-WLUYq3Qzd5RZ-__um_ec03zj5J4nOn8ID8YQkp2UX38Ed-LwGO59GhfJn8Dlyqa4vWF2CCwSQ4T1N2yd2Nb-tsTKMESW1vYH3q4Zhn9s2mtOQtZj8a8dHfC42jyFr-dnX5YX9ZgxofZY3W2tdM-tU7z3QiTree8QNN8HNLwQBGLmoghBSesXkSftUUmhd0I7JzkRy7fP4GBYD_EFMAy0-tSimA6uc145HfEzC4n4e5FkrODoFjjzsxBjGBxQEL6G8DUF3wo-EqiTCLFZ5weoYzPq2PxLxxW8JZWYcjR0sklzQtw5GKFJXcH7LEFWiZpBYMvhAqwL8VvNJA9nkmhNfl58q3YzWvPGiHzhwLCp4N1UTG_SDrUhrncb07SLTmki9K_geWklU6UFJU1UDb6tZu1nhsq8ZLj6nrm-W4oQ2-bl_4DxFdwXOZkHTSAdwsH2ehdfw91N2L3J1vMHb40cJQ priority: 102 providerName: Directory of Open Access Journals |
| Title | Safety and efficacy of tazarotene foam for the treatment of acne vulgaris |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/23696711 https://www.proquest.com/docview/2222229661 https://search.proquest.com/docview/1354790436 https://pubmed.ncbi.nlm.nih.gov/PMC3658431 https://doaj.org/article/d19b4af9d0ad40f0b2219730e6e77028 |
| Volume | 6 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6xPSAuiDehpQSpEqfsJs7D8bFsW7WHIqQFiZvlJ6zEJtU-kNpfz4yTrDbiRg45xJOH52GPnZlvAM505X3hPEs86lNScFMkSuUsUaVjualMxi3tQ14v-Jcf9cUlweSUQy5MCNo3ejltfq-mzfJXiK28W5nZECc2-3o7z2nazLPZBCboGx4s0cPwS3-e8rrLxaMqPLP5_OZiusjRNaEqPIwq2PEsG01EAa__31H5YFoah0wezEFXz-Bp7zzG591HPodHrnkBj2_73-Mv4WahvNvex6qxsSNsCGXu49bHW_WgCI-hcbFv1QpP6xgdv3gfZU5EymDznx2ldiw3r-D71eW3-XXS10pIDPZ2m3BRp0rztDaMeWXSWitbmNqiyVnLUldpx6zllTKlS70wKB5baya0rlKClM9fw1HTNu4txOhi1T5HMmF1oQ3XwuFjykozZpivXARnA-PkXQeJIXEpQayWxGrZsTqCz8TUPQnhWIcL7fqn7KUpbSZ0obywKX5u6lN8RyZw0HGV4xxdnwg-kEhklxS6t0Z5Tqg56JtVIoJPgYLsESWDjO3SCrAvhGw1ojwZUaIdmXHzIHbZ2_FGsnDgkjCL4OO-me6k2LTGtbuNzPKy4IKg_CN402nJvtODskXAR_oz4sq4BZU-oHz3Sv7uv-88hics1O6g_aITONqud-49TDZ2dxp2Hk6D3fwF2c4cFQ |
| link.rule.ids | 230,315,729,782,786,866,887,2106,27933,27934,53800,53802 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB7RIgEX3g9DoUaqxMnJeu147WNJWyWiqZBSJG6rfZZIxK7yQCq_nhnbsWJxqw8-eMaveezO2jPfAJzozPvUeR55tKcoFSaNlEp4pEaOJyYzsbD0HXIyF1c_87NzgskZ7Wph6qR9oxeD8vdyUC5-1bmVt0sz3OWJDb_PxglNm0k8PICH6K-M7S3S6wGY_j0leVONR314huPx9GwwTzA4oT48nHrYiTjuTUU1Yv__4_LexNRPmtybhS6e3fP5n8PTNuwMTxvyC3jgypfwaNb-WH8F07nybnMXqtKGjlAllLkLKx9u1F9FSA6lC32llrhbhRgyhl1-OjEpg-Q_WyoKWaxfw4-L8-vxJGq7LEQGpbSJRJEzpQXLDedeGZZrZVOTW3RWazlzmXbcWpEpM3LMFwYVa3PNC60zRmD0yRs4LKvSvYMQg7PcJ8hWWJ1qI3Th8DKjTHNuuM9cACc7gcvbBkxD4iKEVCRJRbJRUQBfSRkdCyFg1weq1Y1s5ShtXOhU-cIyfFzmGd4jLnC4cpkTAoOmAI5JlbIpJ-38WJ4S3g5GdVkRwJeagzwZNYqCbQoS8F0IE6vHedTjRA80ffLOXGQ7AqwlrzdcTMYBfO7IdCZltZWu2q5lnIxSUVATgADeNtbVvfTOSAMQPbvrSaVPQXOr8cFb83p_7zOP4fHkenYpL6dX3z7AE153AKGvTkdwuFlt3Uc4WNvtp9rr_gENDzCm |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwEB6xi7TiwvsRWNggrcQpreOkcXJc2q22gl2tVJC4WX5CJZpUfSAtv56ZJI0acYMccojHSTwPe2yPvwE415n3qfM88qhPUSpMGimV8EiNHE9MZmJhaR3yai5uvuWTS4LJ6VJ91UH7Ri8G5c_loFz8qGMrV0sz3MeJDW-vxwkNm0k8XFk_PIL7aLOMH0zU606Y9p-SvDmRR7l4huPxbDKYJ-igUC4eTnnsRBz3hqMatf_vvvlgcOoHTh6MRNNH_9GGx_CwdT_Di4bkCdxz5VM4uW432J_BbK68296FqrShI3QJZe7Cyodb9VsRokPpQl-pJd7WIbqOYRenTkTKYPGvHR0OWWyew9fp5ZfxVdRmW4gMcmobiSJnSguWG869MizXyqYmt2i01nLmMu24tSJTZuSYLwwK2OaaF1pnjEDpkxdwXFalewUhOmm5T5CssDrVRujC4WtGmebccJ-5AM73TJerBlRD4mSExCRJTLIRUwAfSSAdCSFh1w-q9XfZ8lLauNCp8oVl-LvMM_xGXGC35TInBDpPAZyROGVzrLSzZ3lBuDvo3WVFAB9qCrJolCoytjmYgG0hbKwe5WmPEi3R9Iv3KiPbnmAjeX3hpDIO4H1XTDUpuq101W4j42SUioKSAQTwstGwrtF7RQ1A9HSvx5V-CapcjRPeqtjrf655Bie3k6n8PLv59AYe8DoRCC0-ncLxdr1zb-FoY3fvasP7A5nUMyY |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety+and+efficacy+of+tazarotene+foam+for+the+treatment+of+acne+vulgaris&rft.jtitle=Clinical%2C+cosmetic+and+investigational+dermatology&rft.au=Epstein%2C+Erica+L&rft.au=Linda+Stein+Gold&rft.date=2013-01-01&rft.pub=Taylor+%26+Francis+Ltd&rft.eissn=1178-7015&rft.volume=6&rft.spage=123&rft_id=info:doi/10.2147%2FCCID.S34054&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1178-7015&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1178-7015&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1178-7015&client=summon |